Navigation Links
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Date:7/2/2009

PALATINE, Ill. and BRISTOL, Tenn., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of moderate-to-severe pain.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090702/DC41417LOGO-a )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090702/DC41417LOGO-b )

The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox(R). Acura and King are currently evaluating the FDA's Complete Response Letter, and at this stage believe they can respond to the issues raised without conducting any additional studies. The Companies plan to meet with the FDA following submission of their response.

About Acurox Tablets

Acurox is a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient with a proposed indication for the relief of moderate-to-severe pain. Acurox utilizes Acura's proprietary Aversion Technology, which is designed to deter misuse and abuse by intentional swallowing of excess quantities of tablets, intravenous injection of di
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
2. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
3. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
5. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/...e pharmaceutical ingredients (APIs), announced tha...ound Safety Certification from,SafeBridge(R) Consu...,s,competency and proficiency in the safe handling...), and applies to specific laboratories and,produc...
(Date:11/19/2009)..., ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCa...YSE: ABT ) as one of its Most Admired Corporate ...Deal honored Abbott as its Most Admired Dealmaker...c use of acquisitions and divestitures since Janua...shaped its business portfolio with a focus on high...
(Date:11/19/2009)... , Part of International Internet Week of Acti...USNewswire/ -- The U.S. Food and Drug Administrati...ational effort, called the International Internet ...tions involving medical products. ,, (Logo: ht... ) ,, During the effort, the FDA,s Office of Cr...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 1Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 2Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 3Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 4Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 5Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 6Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 7Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 8New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 1New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 2New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 3New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 4New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 5Healthcare Trust of America Inc Completes Acquisition of 856 000 SF Greenville Hospital System Medical Office Building Portfolio 57896 1Healthcare Trust of America Inc Completes Acquisition of 856 000 SF Greenville Hospital System Medical Office Building Portfolio 57896 2Healthcare Trust of America Inc Completes Acquisition of 856 000 SF Greenville Hospital System Medical Office Building Portfolio 57896 3
...ment of Ocular Itching Associated with ...f., April 30 ISTA,Pharmaceuticals, Inc. (Nasdaq: ... preliminary analysis of its second and final Bepr...I clinical study. The U.S. multi-center,conjunctiv...set and,duration of effect of two Bepreve concentr...
...., a,biopharmaceutical company developing new ther...e 1 and 2 diabetes, announces its,achievement of a...et,Peptide (HIP). CureDM has successfully stabiliz...dose response studies indicating that the,dosage u...he native form.,HIP is a 14-amino acid human pepti...
Other Medicine Technology:ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 3ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 4CureDM's Diabetes Therapy Achieves Major Development Milestone 2
(Date:11/21/2009)... , "This bill provides for an unprecedente...health care about if it is not for preserving and ... it must be defeated." Charmaine Yoest ,, WA...cans United for Life Action President and CEO Dr. ... Senate by releasing the following statement: ,...
(Date:11/21/2009)... , WASHINGTON, Nov. 21 /PRNewswire-USNewswire...o eliminate onchocerciasis (river blindness) in th...e of the disease in recent years, as evidenced by ...ing mass drug administration in six endemic countr...al meeting of the American Society of Tropical Med...
(Date:11/21/2009)..., LONDON, November 21, 2009 /PRNewswire-Fir... Test Test Test Test Test Test Test Test Test Test... Test Test Test Test Test Test,Test Test Test Test... More test More test More test More test More tes...t More test More test More test More test More,tes...
(Date:11/21/2009)... Innovative medical apparel co...erence , San Clemente, Ca...aker of breakthrough medical apparel, today announ...n display at Medica 2009, a leading international ...dorf, Germany. Medelita inaugurates its men,s coll...
(Date:11/21/2009)... Eric J. Hall, president and c...on of America (AFA) issued the following statement...etection as part of the new annual wellness for Me...on and Affordable Care Act" that was introduc..., NY (PRWEB) November 21, 2009 -- Eric J. Hall, pr...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3
...t Listed on Product Labels Due to Weak Regulatory ...ting claims like "gentle" and "pure," dozens of to...d with the cancer-causing chemicals formaldehyde a...abels because contaminants are exempt from labelin...
...March 12 For the past three decades, employers ha...e costs. Now some are pinning their hopes on a rel..., which link high-deductible health insurance plan...ent in Health Care -- 30 Years into the Experiment...
...perts in cancer and nutrition are meeting in Zuric...edge research in one of the most important and fie...k between diet and cancer. , There is growing ev...so have a negative impact on cancer management and...
...- The long tails sported by many male birds in the...and a distinct disadvantage when fleeing predators...keley, biologists shows that they exact only a min...cent, which means the bird has to visit 1 to 3 per...
...ass., March 12 North American application activit... up +1.1% in February, year-over-year, according t...from January to February 2009 was up +12.9%. Year...butable to the Life Index methodology rather than ...
...Partners Offer Consumers Chance to Win Tickets to ...RSIPPANY, N.J., March 12 alli announced today a s...ity to attend a private Wynonna Judd concert in Na...nd,s spokesperson, in an intimate setting while sh...
Other Medicine News:Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 2Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 3Health News:EBRI Policy Forum: Consumer/Patient Engagement in Health Care - 30 Years On 2Health News:New data on link between cancer and nutrition discussed at European symposium 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:MIB Life Index Reports North American Life Insurance Activity up 1.1% in February 2Health News:MIB Life Index Reports North American Life Insurance Activity up 1.1% in February 3Health News:Wynonna Judd and alli Host Private Concert in Nashville 2
Ocular Three Mirror 10 mm Gonio
Ocular Magna View Gonio
Ocular Koeppe Diagnostic
Mcintyre Cannula
Medicine Products: